Every year, the diabetes community comes together for the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). In the 17th installment at the start of this month, some of the biggest names shared new studies and … [Read More...] about The biggest diabetes tech news out of ATTD 2024
Main Content
Drug Tech
Today on Drug Delivery Business
- FDA clears automated insulin delivery system from Sequel Med Tech
- The biggest diabetes tech news out of ATTD 2024
- Ascensia, Senseonics announce new CGM cost savings
- Boston Scientific has positive Agent DCB study results
- Medtronic highlights global performance of MiniMed 780G automated insulin delivery system
- Innovation Zed, Enhance-D collab on insulin dosing management
- Know Labs has positive accuracy data for non-invasive glucose monitor
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
FDA clears automated insulin delivery system from Sequel Med Tech
By Sean Whooley
Sequel Med Tech announced today that its partner, DEKA R&D, won FDA 510(k) clearance for its automated insulin delivery (AID) system. The twist system, powered by Tidepool, directly measures the volume and flow of insulin delivered with every … [Read More...] about FDA clears automated insulin delivery system from Sequel Med Tech
The biggest diabetes tech news out of ATTD 2024
By Sean Whooley
Every year, the diabetes community comes together for the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). In the 17th installment at the start of this month, some of the biggest names shared new studies and … [Read More...] about The biggest diabetes tech news out of ATTD 2024
Ascensia, Senseonics announce new CGM cost savings
By Sean Whooley
Ascensia Diabetes Care and Senseonics today announced an extension to their Eversense Payment Assistance and Simple Savings (PASS) program. The program aims to help people in the U.S. access the Eversense E3 continuous glucose monitor (CGM) more … [Read More...] about Ascensia, Senseonics announce new CGM cost savings
Boston Scientific has positive Agent DCB study results
By Sean Whooley
Boston Scientific [WtwhTicker symbol="BSX"](NYSE: BSX)[/WtwhTicker] reported positive investigational device exemption (IDE) trial data for its Agent drug-coated balloon (DCB). The DCB just this month won FDA approval for treating coronary … [Read More...] about Boston Scientific has positive Agent DCB study results
Medtronic highlights global performance of MiniMed 780G automated insulin delivery system
By Sean Whooley
Medtronic (NYSE:MDT) shared new clinical and real-world evidence backing the use of its MiniMed 780G system around the world. Data shared at ATTD 2024 in Florence, Italy, included the largest set of data from early users in the U.S. Results built … [Read More...] about Medtronic highlights global performance of MiniMed 780G automated insulin delivery system
Innovation Zed, Enhance-D collab on insulin dosing management
By Sean Whooley
Innovation Zed announced this week that it entered into a strategic partnership with Enhance-D to optimize diabetes therapy. Switzerland-based Enhance-D develops a digital health platform for enhancing diabetes and exercise management. It designed … [Read More...] about Innovation Zed, Enhance-D collab on insulin dosing management
Know Labs has positive accuracy data for non-invasive glucose monitor
By Sean Whooley
Know Labs (NYSE:KNW) announced interim results highlighting the accuracy of its non-invasive glucose monitoring sensor. Seattle-based Know Labs conducted a study evaluating its proprietary radiofrequency (RF) dielectric sensor. The sensor … [Read More...] about Know Labs has positive accuracy data for non-invasive glucose monitor
Insulet shares data demonstrating Omnipod 5’s superiority to pump therapy
By Sean Whooley
Insulet (Nasdaq:PODD) today announced positive results from a clinical trial pitting its Omnipod 5 against non-automated insulin therapy. Acton, Massachusetts-based Insulet conducted its first randomized controlled trial showing improved … [Read More...] about Insulet shares data demonstrating Omnipod 5’s superiority to pump therapy
Roche unveils new CGM tech with predictive AI, outlines diabetes strategy
By Sean Whooley
Roche today gave a presentation debuting its first continuous glucose monitor (CGM) offering that utilizes predictive AI. The company unveiled its Accu-Chek SmartGuide in an event at the Advanced Technologies & Treatments for Diabetes (ATTD) … [Read More...] about Roche unveils new CGM tech with predictive AI, outlines diabetes strategy
Smiths Medical recall affects nearly 86,000 syringe pumps with software issues
By Sean Whooley
Smiths Medical issued a recall for its Medfusion Model 3500 syringe pump due to issues associated with earlier software versions. The ICU Medical unit issued the recall as a correction — not a product removal. It affects 85,961 pumps distributed … [Read More...] about Smiths Medical recall affects nearly 86,000 syringe pumps with software issues
In case you missed it
- Real-world data backs Abbott FreeStyle Libre CGM in tandem with GLP-1s
- Tandem Diabetes Care prices $275M offering
- FDA clears first over-the-counter CGM from Dexcom
- Dexcom announces direct-to-watch feature for G7 CGM, strong automated insulin delivery outcomes
- Know Labs to raise up to $12M for non-invasive CGM tech
- Vivani prices $15M offering to support long-term drug delivery implant
- FDA approves Boston Scientific’s Agent drug coated balloon
- FDA submission for 365-day CGM from Senseonics is ‘imminent’
- Report: Insulet trumps Medtrum again in French patent spat
- These diabetes devices are set to launch in 2024
- Know Labs unveils wearable, non-invasive CGM set for FDA submission
- Irish startup Gasgon Medical looks to raise €4M for IV delivery tech
- Insulet begins limited rollout of Omnipod 5 with Dexcom G7, grows sales by 38% in Q4
- Modular Medical closes $10M public offering
- FDA: Don’t use smartwatches, smart rings to measure blood glucose
Clinical Trials
The biggest diabetes tech news out of ATTD 2024
Every year, the diabetes community comes together for the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). In the 17th installment at the start of this month, some of the biggest names shared new studies and technologies set to advance the diabetes space. Dexcom, Abbott, Medtronic and more contributed on their end, while […]
Medtronic highlights global performance of MiniMed 780G automated insulin delivery system
Medtronic (NYSE:MDT) shared new clinical and real-world evidence backing the use of its MiniMed 780G system around the world. Data shared at ATTD 2024 in Florence, Italy, included the largest set of data from early users in the U.S. Results built upon three-year data from more than 100,000 real-world users who outperformed international time in […]
Know Labs has positive accuracy data for non-invasive glucose monitor
Know Labs (NYSE:KNW) announced interim results highlighting the accuracy of its non-invasive glucose monitoring sensor. Seattle-based Know Labs conducted a study evaluating its proprietary radiofrequency (RF) dielectric sensor. The sensor non-invasively measured blood glucose in participants with prediabetes and type 2 diabetes. It used venous blood as a comparative reference. Know Labs reported a mean […]
Insulet shares data demonstrating Omnipod 5’s superiority to pump therapy
Insulet (Nasdaq:PODD) today announced positive results from a clinical trial pitting its Omnipod 5 against non-automated insulin therapy. Acton, Massachusetts-based Insulet conducted its first randomized controlled trial showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 automated insulin delivery (AID) system. The company presented results at the Advanced Technologies […]
Real-world data backs Abbott FreeStyle Libre CGM in tandem with GLP-1s
Abbott (NYSE:ABT) today announced data from two real-world studies highlighting the success of its CGM when used with GLP-1 drugs. Data showed that people with type 2 diabetes using GLP-1s with FreeStyle Libre had a greater improvement in HbA1c compared to GLP-1s alone. Abbott presented the findings at the Advanced Technologies & Treatments for Diabetes […]